← Back to all trials
Active Not Recruiting
NCT05678192
Effect of Menopausal Hormone Therapy on Immune System Parameters
Conditions: Last Period Not Earlier Than 6 Months Ago
Sex: Female
Ages: 45 Years – 59 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 40
Sponsor: Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Location: Russian Federation
Summary
The objective of the study is to evaluate the effect of menopausal hormone therapy on the parameters of the immune system.
To do this, patients took blood to assess the immune status before the start of therapy and after 3 months.An additional task is to assess the content of blood sex hormones before the start of therapy and after 3 months.
Eligibility Criteria
Inclusion Criteria:age from 45 to 59;phase of reproductive aging - perimenopause, postmenopause or surgical menopause (ovariectomy);indications for prescribing MHTExclusion Criteria:Absolute contraindications to MHT:Bleeding from the genital tract of unknown originBreast and endometrial cancerAcute hepatitisAcute deep vein thrombosisAcute thromboembolismCutaneous porphyriaObesity;HIV infection and other congenital and acquired immunodeficiencies;Systemic connective tissue diseases;Oncological diseases in history;History of chemotherapy and/or radiation therapy;Autoimmune diseases;Acute diseases and exacerbation of chronic diseases during the last 3 months;Reception of immunomodulatory drugs during the last 3 months.
Source: ClinicalTrials.gov (NCT05678192). StuddyBuddy aggregates publicly available trial information.
